Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Average Rating of “Buy” from Analysts

Trevi Therapeutics, Inc. (NASDAQ:TRVI) has been given a consensus recommendation of “Buy” by the twelve ratings firms that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, nine have issued a buy rating and two have given a strong buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $24.9091.

A number of equities research analysts have issued reports on the stock. Morgan Stanley reiterated an “overweight” rating and set a $20.00 price objective on shares of Trevi Therapeutics in a research note on Wednesday, May 6th. Stifel Nicolaus set a $30.00 price objective on shares of Trevi Therapeutics in a research note on Friday, May 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Trevi Therapeutics in a research report on Friday, July 17th. BMO Capital Markets began coverage on Trevi Therapeutics in a research note on Monday, July 20th. They set an “outperform” rating and a $36.00 target price for the company. Finally, Wall Street Zen downgraded Trevi Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, July 25th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of TRVI. Russell Investments Group Ltd. lifted its holdings in shares of Trevi Therapeutics by 194.5% in the second quarter. Russell Investments Group Ltd. now owns 4,536 shares of the company’s stock worth $25,000 after acquiring an additional 2,996 shares during the last quarter. KBC Group NV bought a new stake in shares of Trevi Therapeutics during the 1st quarter valued at approximately $29,000. Hilton Head Capital Partners LLC acquired a new position in Trevi Therapeutics during the 4th quarter worth approximately $40,000. Caitong International Asset Management Co. Ltd bought a new position in Trevi Therapeutics in the 4th quarter valued at approximately $50,000. Finally, Strs Ohio bought a new position in Trevi Therapeutics in the 1st quarter valued at approximately $52,000. Institutional investors own 95.76% of the company’s stock.

Trevi Therapeutics Price Performance

Trevi Therapeutics stock opened at $18.50 on Friday. The firm has a market cap of $2.63 billion, a PE ratio of -57.81 and a beta of 1.03. The stock’s fifty day moving average price is $16.88 and its two-hundred day moving average price is $13.97. Trevi Therapeutics has a one year low of $6.55 and a one year high of $20.22.

Trevi Therapeutics (NASDAQ:TRVI) last released its earnings results on Thursday, August 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.11). Sell-side analysts expect that Trevi Therapeutics will post -0.47 earnings per share for the current fiscal year.

About Trevi Therapeutics

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.